Research programme: Gram-positive infection therapeutics - ContraFect

Drug Profile

Research programme: Gram-positive infection therapeutics - ContraFect

Alternative Names: CF 302; CF 303; CF 304; CF 305; CF 306; CF-307; CF-308; CF-309; Gram-positive lysins - Contrafect

Latest Information Update: 24 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rockefeller University
  • Developer ContraFect
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Cell membrane inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Anthrax; Enterococcal infections; Pneumococcal infections; Streptococcal infections

Most Recent Events

  • 24 Nov 2016 Early research of CF 305 for Streptococcal agalactiae infections in USA (unspecified route) before November 2016 (Contrafect pipeline, November 2016)
  • 19 May 2014 Early research in Anthrax in USA (unspecified route)
  • 19 May 2014 Early research in Enterococcal infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top